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Research Highlights 
 SPE UPLC-Q-Exactive Orbitrap method was developed and validated for analysis 
of 30 PPCPs 
 Rapid ESI polarity switching for analysis of acidic and basic analytes in one run 
 Full scan MS mode allows for post-acquisition non-target screening 
 First target/non-target report of PPCPs in waste/surface water from Egypt 
 
Abstract 
The analytical capability of the UPLC-Q Exactive™ Orbitrap MS was exploited for 
simultaneous determination of 30 acidic and basic PPCPs in a single run, using rapid 
polarity switching of the electrospray ionisation source. Full scan MS mode at resolution 
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of 35000 FWHM, Automatic gain control (AGC) target of 1E6 ions at injection time of 50 
ms provided the optimum parameters for high sensitivity, together with sufficient data 
points per peak (≥15) for improved reproducibility. In addition to chromatographic 
retention times, method selectivity was achieved via applying high resolution accurate 
mass with low mass tolerance filter (<5 ppm) for identification of each target 
compound. Six-point linear calibration curves (R2 > 0.95) were established for all target 
analytes over a concentration range of 1-1500 ng/ml. Good results were obtained for 
method accuracy (% recovery = 76–104%), inter- and intra-day precision (relative 
standard deviation <15%) at 3 concentration levels. Instrumental detection and 
quantification limits ranged from (0.02–1.21 ng/ml) and (0.07–4.05 ng/ml), 
respectively. While optimised MS/MS analysis through parallel reaction monitoring 
(PRM) mode provided slightly higher sensitivity, Full scan MS mode allowed for higher 
mass resolution (selectivity), more data points per peak (reproducibility) and more 
importantly, the potential for post-acquisition screening of non-target compounds. 
Following solid phase extraction (SPE) of target analytes, the method was successfully 
applied to provide first data on PPCPs occurrence in effluent and surface water samples 
(n=10) from Egypt. Moreover, screening for non-target compounds revealed the 
presence of bisphenol A, which was further confirmed via matching with an authentic 
standard. Overall, this study provides first insight into the high analytical capabilities of 
the Q-Exactive™ Orbitrap platform for both targeted/non-targeted analysis of PPCPs in 
environmental matrices.    
 
Keywords: Q Exactive Orbitrap; Pharmaceuticals and personal care products; surface 
water; effluent; Egypt; non-target screening 
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Introduction 
Pharmaceuticals and personal care products (PPCPs) represent a large group of 
chemicals with diverse structures and physicochemical properties. Pharmaceuticals 
include all prescription, over the counter and veterinary drugs used for prophylaxis or 
treatment of human or animal diseases, while personal care products are those applied 
mainly to improve the quality of daily life [1]. Pharmaceuticals are inherently potent, 
biologically-active chemicals, designed to achieve maximum bioavailability and 
prolonged duration of action in target organisms. The unintentional presence of a large 
number of PPCPs in the environment (water, sediment and biota) has received 
increasing scientific interest in the past few years.  This has been mainly attributed to 
the inefficient removal of these chemicals during conventional waste water treatment 
processes [2, 3]. Other sources include the application of contaminated sewage sludge 
for fertilisation of soil and the leaching of agricultural run-off water to ground water 
reservoirs [2]. Currently, very little is known about the behaviour and fate of this large 
group of chemicals once released to the environment. This is of concern owing to the 
continuous input of PPCPs to the environment, together with the reported, persistence, 
bioaccumulative and toxic characters of various members of this group [1, 4, 5]. This is 
compounded by the current lack of knowledge on the impact of various PPCPs in the 
ecosystem on non-target organisms (e.g. fish, zooplankton, algae) [1].   
The current status of PPCPs as emerging contaminants of high concern necessitates the 
development of sensitive, selective and accurate methods for determination of trace 
levels of these chemicals in various environmental compartments. Moreover, the large 
number of PPCPs requires the use of multi-residue, rapid and robust analytical methods 
to provide maximum possible information on the levels and profiles of these chemicals 
in each sample within reasonable time and cost of analysis [6]. To address this, 
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advanced methods using hyphenated liquid (LC) or gas chromatography (GC) and mass 
spectrometry (MS) techniques have been reported for analysis of PPCPs in the past few 
years [7, 8]. Due to their relatively hydrophilic nature, LC-MS is reported as the method 
of choice for multi-residue analysis of pharmaceuticals, endocrine disruptors, and illicit 
drugs, especially for thermally unstable chemicals [9]. Ultra-high pressure liquid 
chromatography (UPLC) displayed superior performance to conventional HPLC due to 
reduced particle size of the stationary phase. This results in enhanced resolution, 
narrower peaks and shorter run times [10]. Reversed phase (C18 or C18-bonded phases) 
has been the most widely used mechanism of LC separation due to its versatility and 
capacity for separation of a broad range of compounds [8]. In terms of sample 
preparation, solid phase extraction (SPE) is the most popular and well-established 
technique for PPCPs in liquid environmental samples. Several SPE adsorbents with 
varying strength cation and/or anion exchange copolymers were reported to provide 
high extraction efficiency with low matrix-related interference for determination of 
different groups of PPCPs [10, 11].   
However, rapid, sensitive and accurate multi-residue analysis of trace concentrations of 
PPCPs in complex environmental matrices continues to be a fascinating challenge. This 
is mainly driven by the continuous advance in analytical instrumentation leading to 
higher sensitivity, improved selectivity and wider dynamic range. The quadrupole (Q)-
Orbitrap high resolution mass spectrometer (Q-Orbitrap/MS) is a good example of such 
advances. It provides mass resolution up to 280,000 full width at half maximum 
(FWHM), with acquisition speed of 12 Hz. This results in mass accuracy < 1 ppm and a 
linear dynamic range spanning 5 orders of magnitude. An important feature of the Q-
Exactive Plus Orbitrap™ (Thermo Fisher Scientific, Bremen, Germany) is the rapid 
polarity switching between positive and negative ionisation modes in the heated 
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electrospray ionisation (HESI) source within a full cycle in <1 s. Moreover, the 
quadrupole adds another dimension by possible preselection of 10 precursor ions/scan. 
The selected precursor ions then undergo collision-induced fragmentation in parallel 
reaction monitoring mode (PRM) in order to conduct MS/MS analysis [12]. The cutting-
edge technology of the Q-Exactive Orbitrap™ combined with the high separation power 
of UHPLC provides an excellent platform for analysis of complex chemical mixtures like 
PPCPs in environmental samples. To our knowledge, the analytical capability of this 
platform has yet to be fully explored for the purpose of PPCPs analysis. A survey of the 
literature revealed one analytical study using UHPLC-Q-Exactive Orbitrap™ for 
determination of 13 PPCPs in 2 runs for positively (12) and negatively (1) ionised 
compounds, separately [13]. This is similar to previously reported LC-MS/MS studies 
using other instruments, where 2 separate runs are required for multi-component 
analysis. In addition, the targeted MS/MS approach does not allow for retrospective 
screening approaches for identification of potential compounds of interest which were 
not targeted in the original analytical protocol [10, 14].  
Therefore, the current study aims to exploit the full potential of the UHPLC-Q-Exactive 
Orbitrap™ platform for analysis of 30 PPCPs as representatives of different groups 
including: antibiotics, antiseptics, β-blockers, NSAIDs, narcotic analgesics, anti-
hyperglycaemic agents, proton-pump inhibitors and insect-repellents (Table 1). 
Selection was based on priority pollutant lists developed by the European Union (EU) 
under the Water Framework Directive (WFD), as well as the United States 
Environmental Protection Agency (USEPA). Other selection criteria include: frequent 
environmental occurrence, persistence and toxicity to aquatic organisms [1]. The 
method aims to utilise the rapid polarity switching of the HESI source and the 
separation power of the UHPLC to achieve maximum separation in a single run within a 
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reasonably short analysis time. The developed method is validated and applied to 
provide insights into the levels and profiles of PPCPs in 10 effluent and surface water 
samples from Egypt. Furthermore, the advantage of acquiring full-scan high resolution 
MS data via the Orbitrap is explored for possible screening and identification of non-
target compounds in the studied water samples.   
Materials and Methods 
Chemicals and Reagents 
All solvents used in this study were purchased from Fisher Scientific™ (Loughborough, 
UK) and were of UPLC grade. Individual standards of 30 PPCPs (Table 1), in addition to 
isotope-labelled Caffeine-D9, Codeine-D3, Carbamazapine-D10, Estone-D4 and 4-
Chlorophenol-2,3,5,6-D4 used as internal (surrogate) standards were purchased from 
Sigma-Aldrich™ (Irvine, UK) at the highest  possible purity (>99 %). 13C-
tetrabromobisphenol A (13C-TBBPA) and tris (2-chloroethyl) phosphate-D12 (TCEP-
D12) used as recovery (syringe standards) were obtained from Wellington Laboratories 
(Guelph, ON, Canada). All standard stock solutions were prepared and further diluted in 
methanol. Oasis MCX and Oasis HLB cartridges (6 cm3, 150 mg sorbent per cartridge) 
were obtained from Waters™ (Hertfordshire, UK). Ammonium formate (NH4COOH), 
Na2EDTA, ammonium hydroxide (NH4OH, 30 %), ammonium fluoride (NH4F), Acetic 
acid and formic acid (HCOOH) were obtained from Sigma-Aldrich™ (Gillingham, UK). 
Nitrogen gas (oxygen free, 99.998%) was purchased from BOC (Birmingham, UK). Milli-
Q water (Merck Millipore, Burlington, MA) was used for cleaning and sample 
preparation purposes.   
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Sampling 
Water samples (1 L) were collected from the effluent of 5 waste water treatment plants 
(WWTPs) at Assiut governorate, Egypt.  These include 3 major WWTPs in Assiut city (Al 
Helaly, Nazalat- Abdellah and El Walidiyaah), the water treatment plant of Sodfa town, 
in addition to the water treatment plant of Assiut University hospital (Figure SI-1). 
Furthermore, surface water samples were collected from the River Nile and El-
Ebrahmiya canal in Assiut city. These were grab samples collected upstream of the 
WWTP discharge point in deactivated glass bottles and transferred immediately to the 
lab, where they were kept at 4 °C until extraction within 48 hours of collection.    
Sample preparation 
Individual and mixture stock solutions (0.5 g/L) of the targeted PPCPs (Table 1) were 
prepared in methanol and stored in dark amber vials at -20 °C. Working solutions were 
prepared fresh daily by diluting the stock solutions to the required final concentration 
and were stored at 4 °C for a maximum of 24 h. The isotope labelled internal standards 
were prepared and mixed separately at 1 ng/µL in methanol and kept in dark amber 
vials at -20 °C.  
Environmental water samples were extracted by solid phase extraction (SPE) using 
Oasis MCX 6 ml cartridges and Waters™ 20-port controlled pressure vacuum manifold 
equipped with 50Hz vacuum pump (Waters, Hertfordshire, UK). The SPE cartridges 
were pre-conditioned with 3 mL of methanol following by 3 mL of Milli-Q water. 250 mL 
of the water sample were spiked with 100 ng of isotopically-labelled internal standards 
mixture and treated with 500 mg Na2EDTA to release the free form of target analytes 
(e.g. Doxycyclin) from potential complexes with Ca2+ and Mg2+ in environmental waters 
[15]. The samples were loaded onto the pre-conditioned cartridges at a flow rate of 5 
mL/min. The cartridges were washed with 3 mL of 0.5 % HCOOH in Milli-Q water (3 
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mL/min). After drying, PPCPs were eluted with 5 mL of methanol following by 5 mL of 5 
% NH4OH in methanol. The combined eluate was dried under a gentle stream of 
nitrogen using a TurboVap II® evaporator (Biotage™, Sweden) and reconstituted in 100 
μL of methanol containing 25 pg/µL of 13C-TBBPA and TCEP-D12 used as recovery 
(syringe) standards for QA/QC purposes. 
Instrument Analysis 
Samples were analysed on a UPLC-Q Exactive Orbitrap-HRMS system (Thermo Fisher 
Scientific™, Bremen, Germany) composed of a Dionex Ultimate 3000 liquid 
chromatograph equipped with a HPG-3400RS dual pump, a TCC-3000 column oven and 
a WPS-3000 auto sampler. The UPLC is coupled to a Q-Exactive Plus Orbitrap mass 
spectrometer equipped with a heated electrospray ionisation (HESI) ion source. 
Chromatographic separation was achieved on an Accucore RP-MS column (100 x 2.1 
mm, 2.6 µm) with 2 mM NH4COOH/2mM NH4F in water (mobile phase A) and 0.5 % 
acetic acid in methanol (mobile phase B). A gradient method at 400 µL/min flow rate 
was applied as follows: start at 2 % B, stay for 1 min; increase to 98 % B over 11 min, 
held for 1 min; then decrease to 2 % B over 0.1 min; maintained constant for a total run 
time of 16 min. Injection volume was 5 μL. The Orbitrap parameters were set as follows: 
alternate switching (-)/(+) ESI full scan mode, sheath gas flow rate 20 AU, discharge 
volage 4.5 kV, capillary temperature 320 °C, resolution 35000 FWHM, AGC target 1E6, 
maximum injection time (IT, the maximum time allowed to obtain the set AGC target) 
50 ms and scan range 125 to 750 m/z. MS/MS analysis using PRM was also attempted. 
The chromatographic and Orbitrap MS parameters were the same as in full scan 
acquisition, except for: AGC target 2E5, maximum IT 100 ms and resolution 17,500 
FWHM). 
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Method Validation and quantification 
Method linearity was investigated via triplicate injections of 6 point calibration curve 
for each of the studied analytes over a concentration range of 1 – 1500 ng/mL, using a 
fixed concentration of 100 ng/mL of the isotope labelled IS. Linearity was evaluated 
through the linearity coefficients (R2) of the obtained calibration curves. 
Other method validation parameters were calculated using Milli-Q water spiked with 
the target PPCPs at 3 concentration levels (10, 250 and 750 ng/mL). 
Accuracy was estimated as the percentage recovery of target analytes and evaluated 
through the percent deviation from the known spiked concentration level.  
Precision was calculated as relative standard deviation (RSD %) for inter- and intra-day 
multiple injections. Nine injections covering 3 concentration levels (3 injections each) 
were used for assessment of precision. Further validation of method precision was 
performed via calculation of the RSD % for triplicate analyses of 3 different samples 
(tapwater spiked with 500 ng/L of all target PPCPs, surface water from the River Nile 
(2G) and effluent sample (1A)). The tapwater was collected in the lab and allowed to 
stand for 30 min for evaporation of Cl2 prior to further processing.   
Limit of detection (LOD) and limit of quantification (LOQ) were estimated using the 
signal to noise (S:N) approach. Instrumental detection limit (IDL) was calculated as the 
lowest concentration that gives a S:N ratio of 3:1, while Instrumental quantification 
limit (IQL) was calculated as the lowest concentration that gives a S:N ratio of 10:1.  
Method quantification limits (MQL) were determined by repeated injection of tapwater 
samples spiked at low concentrations of target compounds.  The concentration that 
produces a S:N ratio of 10 was estimated as the MQL.  
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Quality assurance/quality control (QA/QC)   
None of the target compounds were detected in method blanks (one blank for every 5 
samples; each blank is composed of 250 mL Milli-Q water treated like a sample). 
Therefore, no blank correction of the results was required.  
Recoveries of the isotope-labelled internal standards were calculated against the 
syringe standards in all environmental and QA/QC samples. High percent recoveries 
(>70 %) of all five internal standards were obtained indicating good overall 
performance of the method. 
A calibration standard containing all the target compounds and IS (500 ng/mL) was 
injected before and after each sample batch (Figure 1). For a given peak to be identified 
as a target analyte in a sample; the relative retention time (RRT) of the peak in the 
sample must be within ± 0.1 min of the average value determined for the same analyte 
in the 2 calibration standards ran before and after that sample batch. 
Results and Discussion 
Method Optimisation 
Solid phase extraction was documented by several authors as the method of choice for 
PPCPs in wastewater samples using various sorbent beds [8]. In the current study, we 
tested two of the most widely reported sorbent beds for extraction of various PPCPs, 
namely: Oasis MCX and Oasis HLB. A paired t-test for comparison of means revealed no 
significant differences between the recoveries of target analytes in spiked tap water 
samples (500 ng/L of all target PPCPs, n=3) from both solid phases (Figure SI-2). 
However, it was generally observed that a higher chromatographic baseline and more 
spectral interference occurred in real effluent samples extracted with HLB cartridges 
compared to MCX (Figure 2). This is in agreement with the results of Petrie et al. [6] and 
can be attributed to the non-selective nature of the hydrophilic-lipophilic balanced, 
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reversed-phase HLB sorbent bed, which can cause significant matrix-related 
interferences when using ESI mode [16]. Therefore, Oasis MCX, which is built upon the 
HLB copolymer with mixed mode cation-exchange and reversed phase interactions, was 
applied for extraction of all our samples.   
Although baseline chromatographic separation of all analytes was not targeted due to 
subsequent MS analysis (Figure 1), the method was optimised towards achieving a 
better peak shape and higher intensity in subsequent ESI ionisation. Therefore, a simple 
mobile phase gradient based on H2O and methanol was chosen due to the observed 
overall reduction of ESI signal intensity when using acetonitrile compared to methanol. 
This may be attributed to the reduced charge status of ionised species in the 
electrospray droplets by the neutral vapour of acetonitrile in the atmospheric region of 
the source [17]. Acetic acid buffer had a substantial effect on enhancing the peak shape 
and signal intensity of basic analytes (Figure SI-3) via promoting their protonation in 
ESI positive mode [18]. Moreover, the use of NH4F as a mobile phase additive resulted in 
significant enhancement of signal intensity for the steroid hormones 17α-
ethinylestradiol and β-estradiol by 360 % and 480 %, respectively. Petrie et al. reported 
more than 400 % increase in the signal intensity for the steroid hormones E1 and E2 
upon using NH4F as a mobile phase additive for LC-ESI(-ve)-MS/MS analysis [6]. 
Similarly, Carmona et al. reported NH4F to improve the peak shape and signal intensity 
compared to ammonium formate for LC-ESI(-ve)-MS/MS analysis of various PPCPs 
including indomethacin, ibuprofen, diclofenac and gemfibrozil [19]. This may be 
explained by the strong electronegativity of the [F]ˉ anion, which enhances 
deprotonation of the acidic analytes in ESI negative mode [19]. In the current study, 
NH4F was used mainly due to significant enhancement of the signals for steroid 
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hormones, while its influence on other acidic analytes (e.g. ibuprofen, diclofenac and 
gemfibrozil) was less evident (Figure SI-4). 
Several mass spectrometric parameters were optimised to maximise method sensitivity 
and achieve the highest signal/noise (S/N) ratio for the studied compounds. While the 
Q-Exactive Orbitrap™ enables very high mass resolution (up to 280,000 FWHM), the 
scan (dwell) time increases with increasing mass resolution. Long dwell time per scan 
cycle results in broad chromatographic peaks due to few data points acquired per each 
peak as it elutes from the column. This ultimately leads to reduced overall sensitivity 
and quantitative reproducibility of the analytical method. Therefore, a minimum of 8-10 
data points across an LC peak is required to define its shape and enable reproducible 
quantitation based on area under the peak, while an optimum of 15-20 points are 
required to expose subtle peak-shape features [20]. Another unique feature of the 
Orbitrap MS is the automatic gain control (AGC), which defines the maximum number of 
ions (from 2 × 104 - 4 × 106) to be injected into the mass analyser within a specified 
injection time (IT). To optimise for these multiple parameters, we adopted a systemic 
approach for each target analyte by studying the concomitant impact of mass resolution 
(up to 280,000 FWHM) and AGC (up to 4 x 106) on the peak area of the studied 
compound (Figure 3) with defined IT of 50 milliseconds and a minimum of 15 data 
points per peak. Despite few non-significant variations for a few compounds, results 
revealed the optimum MS parameters for the overall method as: resolution = 35000 
FWHM, AGC target = 1 x 106 ions and IT = 50 ms.  
Method selectivity and minimisation of potential interferences from co-extracted 
molecules in real samples were achieved via monitoring the molecular ion peak for each 
of the target compounds using its specified accurate mass (Table 1) with the following 
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filters applied: maximum mass tolerance of 5 ppm, retention time window of 20 
seconds and relative retention time (to the designated labelled IS) window of 5 seconds. 
The extracted ion chromatograms (EIC) according to these filters showed well-defined 
correctly identified and appropriately integrated peaks in the studied real samples. 
Method Validation 
Calibration curves showed good linearity of the method over a wide concentration 
range (1-1500 ng/mL) for all the studied PPCPs with a mass error <5 ppm at 35000 
FWHM. The linearity coefficient (R2) exceeded 0.99 for all target PPCPs except for 6 
analytes where it ranged from 0.95 – 0.98 (Table 2). Average percent recoveries of all 
analytes ranged from spiked Milli-Q water samples ranged between 76-104 % at 3 
concentration levels (Table 2) with no statistically significant difference between the 
recoveries of each analyte at the different concentration levels (Table SI-2), indicating 
good accuracy of the method. Potential matrix effects were investigated via triplicate 
analysis of spiked tap water (500 ng/L of all target PPCPs) with recoveries ranging from 
78 – 106 % (Table SI-3). Furthermore, an effluent sample (1A) and a surface water 
sample (2G) (Figure SI-1) were spiked with 500 ng/L of oxazepam (ionizes in ESI 
positive mode) and 17α-ethinylestradiol (ESI negative), which were not detected in 
these 2 water samples. Good recoveries of 103 ± 8 % and 78 ± 11 % were obtained for 
oxazepam and 17α-ethinylestradiol, respectively. However, the difference between the 
average recovery of oxazepam from real water samples (103 ± 8 %) and that from 
spiked tap water (92 ± 8 %) may indicate potential matrix-related effects, which have 
been previously reported with ESI ionisation [15]. Evaluation of matrix suppression of 
the ESI signal for target analytes was performed using the matrix-matched calibration 
method described by Kasprzyk-Hordern et al. (2008)[21]. Results revealed higher 
matrix suppression of the studied PPCPs in effluent (7 – 49%) compared to surface 
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water (5 – 44%) (Table SI6).     Full evaluation of the extent of matrix effects and their 
influence on the accuracy of determination of various PPCPs in environmental waters is 
difficult due to existing levels of PPCPs in real water samples as a result of their 
ubiquitous status in the aquatic environment [1]. Therefore, inter-laboratory studies 
and development of certified reference materials for PPCPs in environmental water 
samples is highly recommended. 
Investigation of the method inter- and intra-day repeatability at 3 concentration levels 
revealed RSD values <15 % for all the studied compounds (Table 2). In addition, 
triplicate analysis of spiked tapwater, effluent (1A) and surface water (2G) samples also 
showed RSD values <15 % indicating good precision of the developed method (Table SI-
4). 
Method sensitivity is demonstrated by the limits of detection and quantification (Table 
2). Our method quantification limits ranged from 2 - 84 ng/L in tapwater, which is in-
line with previously reported UPLC-MS/MS methods for analysis of PPCPs in 
environmental water [10]. Combined with the inherent advantages of rapid ESI-polarity 
switching, high mass resolution (35000 FWHM) and low mass tolerance (< 5 ppm) of 
the Orbitrap, this makes the developed method suitable for determination of trace level 
PPCPs in environmental water samples (e.g. surface water).   
Full Scan vs MS/MS analysis using the Q-Exactive Orbitrap™ 
The Q-Exactive Orbitrap™ used in this study is equipped with a quadrupole filter that 
allows preselection of 10 precursor ions to undergo collision induced dissociation (CID), 
prior to high resolution mass scanning of the produced fragments in the Orbitrap 
analyser (i.e. MS/MS analysis). It is generally perceived that MS/MS analysis provides 
higher sensitivity than MS methods by minimising baseline interferences resulting in 
higher S/N ratios [22]. However, this is largely accepted when comparing the results of 
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tandem MS/MS analysis to single, low mass resolution MS but has not been fully 
evaluated for the high resolution Orbitrap MS applied in the current study.  Therefore, 
we considered MS/MS analysis of our target PPCPs to exploit the full potential of the 
instrument. Since only 10 precursor ions can be selected, the acquisition method was 
divided into several time windows to monitor our 30 analytes and 5 istotope-labelled 
internal standards. This challenges the method capacity for analysis of a large number 
of compounds due to limited number of precursor ions in each time window. 
Furthermore, it is generally recommended to allow a tolerance margin of ±0.5 min for 
analyte retention times in each time window to account for slight changes in retention 
times due to sample matrix effects and column aging [13]. However, this was not 
possible in our method due to the large number of compounds eluting at close retention 
times between 7.97 to 11.54 min (Table 1) resulting in “narrow” time windows (±0.3 
min), which reduces the overall robustness of the method. As reported previously [13], 
the use of the quadrupole increases the time of the scan cycle, which requires 
decreasing the orbitrap mass resolution to 17500 FWHM and the AGC target to 2x10-5 to 
obtain sufficient number of data points (>10) across each peak.  
The precursor ions, major fragment ions, optimised collision energy and estimated IQLs 
for all target PPCPs, obtained from injection of standard solutions are provided in Table 
SI-5. However, it is evident that there is no substantial improvement of sensitivity in the 
MS/MS mode compared to the full scan mode to mitigate for the reduced method 
robustness, AGC target and mass resolution associated with the MS/MS mode in this 
instrument. This may be attributed to the high resolution (35000 FWHM) and low mass 
tolerance (<5 ppm) enabled by the Orbitrap in full scan mode, which reduces potential 
co-eluted interferences resulting in a low baseline and high S/N ratio. 
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The rapid, high resolution full scan MS analysis enabled by the Orbitrap provides 
another major advantage, as it enables post-acquisition independent data analysis. This 
allows screening for non-target compounds in the studied samples, which is beneficial 
to PPCPs monitoring in environmental samples due to the great diversity of this 
contaminant class. To illustrate, post-acquisition screening of our effluent and surface 
water samples revealed the potential presence of bisphenol A, which is a common 
environmental contaminant that was not targeted in our method. The identity of 
bisphenol A was then confirmed via comparison of its accurate mass, retention time and 
molecular ion cluster to an authentic chemical standard. Further confirmation of 
bisphenol A identity was achieved via sample fortification with the authentic standard 
resulting in boosting the area of the designated chromatographic peak (Figure 4). 
Investigation of our method blanks revealed the detection of Bisphenol A in 3 out 8 
blanks with peak areas less than 5% of those detected in the real water samples. While 
this does not allow for accurate quantification of bisphenol A in our samples, it 
demonstrates the potential for combined target/non-target approaches for PPCPs 
analysis using the high resolution, full scan mode of the Orbitrap. 
Method Application 
The developed method was applied for simultaneous determination of 30 target PPCPs 
in 5 effluent and 5 surface water samples collected from Assiut Governorate, Egypt. 
Apart from the anti-malarial compounds mefloquine HCl and DEET, all target PPCPs 
were successfully, detected and quantified in at least one of the studied samples (Table 
3). The method showed good robustness with real samples, with none of the 
compounds shifting outside its specified retention time window. The applied high 
resolution and low mass tolerance resulted in low chromatographic baselines and well-
defined peaks, which is advantageous for accurate integration of peak areas by the 
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Xcalibur™ software. To our knowledge, this is the first report of PPCPs in environmental 
water samples from Egypt. Apart from the anti-malarial drugs Mefloquine and DEET, all 
target PPCPs were detected and quantified with high mass accuracy (<5 ppm) at high 
mass resolution (35000 FWHM) in one or more of the studied water samples. Our 
results show high levels of acetaminophen (144-16000 ng/L), ibuprofen (26-6700 
ng/L) and glyburide (253-4150 ng/L), which were detected in all samples. This is 
generally consistent with concentrations of these compounds reported in effluent and 
surface water samples from South Africa [23] and Nigeria [24]. However, it should be 
noted that PPCPs levels in water are largely dependent on the usage patterns and 
prescription frequencies in the studied area and may vary significantly between 
different countries or geographical areas [1]. Therefore, the absence of anti-malarial 
drugs in the studied water samples may be attributed to the very low incidence of 
malaria in Egypt compared to west and south African countries [25].  
Conclusion 
A sensitive, rapid and robust UPLC-Q-Exactive™ Orbitrap high resolution MS method 
was developed and validated for mutli-residue analysis of 30 PPCPs. The method 
applies rapid polarity switching in the heated ESI source for simultaneous analysis of 
positive and negative ionised compounds in one chromatographic run of 16 min. The 
method’s high resolution (35000 FWHM) and low mass tolerance (<5 ppm) minimises 
potential interference from co-eluted compounds and provides a low chromatographic 
base-line, leading to high S/N ratios in extracted ion chromatograms of the target 
compounds. This resulted in high sensitivity of the full scan MS method comparable to 
the performance of MS/MS analysis. Moreover, full scan MS analysis provides the added 
advantage of post-acquisition screening for non-target compounds. The method was 
applied successfully to provide the first data on levels of target PPCPs in effluent and 
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surface water samples from Assiut, Egypt. Post-acquisition screening for non-target 
compounds revealed the presence of bisphenol A, which was further confirmed via 
matching with an authentic standard. Overall, this work demonstrates the high 
analytical capabilities of the Q-Exactive™ Orbitrap and provides the first insight into the 
potential of this platform for both targeted/non-targeted analysis of PPCPs in 
environmental matrices.   
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Figures 
Figure 1: Reconstructed UPLC-Q-Exactive™ Orbitrap/MS chromatogram of target PPCPs and IS (500 ng/mL in methanol).  
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Figure 2: Total ion chromatogram of effluent sample 1A following SPE on (a) OASIS HLB crtridge (higher baseline) and (b) Oasis MCX 
(lower baseline). Inset shows the extracted ion chromatogram for Diazepam at m/z = 285.07928 (representative example ) with a 
higher baseline in the Oasis HLB sample. 
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Figure 3: Representative example showing the impact of mass resolution (FWHM), Automatic gain control target (ions) on the peak are 
of Nicotine (750 ng/mL) and the number of data points per selected peak. 
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Figure 4: Post-acquisition identification of non-targeted Bisphenol A in the studied water samples through its accurate mass, isotope 
cluster and confirmation by fortification with Bisphenol A standard.  
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Tables 
 
Table 1: List of target PPCPs and their chemical formula, accurate mass, ESI mode, retention time (tR), as well as the internal (surrogate) 
standards used for quantification.   
Name Therapeutic 
group 
Chemical 
formula 
Ionisation  Mass 
(Da) 
tR 
(min) 
Internal  
standard 
Metformin Anti-diabetic C4H11N5 +ve 130.10884 0.64 Codeine-D3  
(tR= 4.63 min) 
Nicotine Stimulant C10H14N2 +ve 163.12318 3.43 Codeine-D3 
Acetaminophen Analgesic C8H9NO2 +ve 152.07143 3.46 Codeine-D3 
Amoxicillin Antibiotic C16H19N3O5S +ve 366.09687 3.53 Codeine-D3 
Gabapentin Anti-convulsant C9H17NO2 +ve 172.13417 3.65 Codeine-D3 
Codeine Narcotic 
analgesic 
C18H21NO3 +ve 300.16089 4.69 Codeine-D3 
Caffeine Stimulant C8H10N4O2 +ve 195.08862 5.17 Caffeine-D9 
(tR= 5.13 min)  
Trimethoprim Anti-bacterial C14H18N4O3 +ve 291.14540 5.40 Codeine-D3 
Sulfamethoxazole Anti-bacterial C10H11N3O3S +ve 254.05949 5.50 Caffeine-D9 
Tramadol Narcotic 
analgesic 
C16H25NO2 +ve 264.19584 6.20 Codeine-D3 
Metoprolol Beta-blocker C15H25NO3 +ve 268.19076 6.33 Codeine-D3 
Doxycycline Antibiotic C22H24N2O8 +ve 445.14963 7.47 Codeine-D3 
Propranolol Beta-blocker C16H21NO2 +ve 260.16433 7.97 Codeine-D3 
Carbamazepine Anti-convulsant C15H12N2O +ve 237.10333 8.49 Carbamazepine-D10 
(tR= 8.49 min) 
Hydrocortisone Steroid C21H30O5 +ve 363.21686 8.67 Carbamazepine-D10 
Naproxen NSAID C14H14O3 -ve 229.08824 9.05 4 Chlorophenol-D4  
(tR= 8.05 min) 
DEET insect repellant C12H17NO +ve 192.13931 9.07 Carbamazepine-D10 
Erythromycin Antibiotic C37H67NO13 +ve 734.47192 9.14 Carbamazepine-D10 
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Oxazepam Sedative,  
hypnotic 
C15H11ClN2O2 +ve 287.05860 9.17 Carbamazepine-D10 
Valsartan Anti-hypertensive C24H29N5O3 -ve 434.22117 9.56 4 Chlorophenol-D4  
Mefloquine Anti-malarial C17H16F6N2O +ve 379.12231 9.78 Carbamazepine-D10 
17α-ethynylestradiol Steroid C20H24O2 -ve 295.17047 9.87 Estone-D4 
(tR= 9.91 min) 
β-estradiol Steroid C18H24O2 -ve 271.16998 9.88 Estone-D4 
Diazepam Sedative,  
hypnotic 
C16H13ClN2O +ve 285.07928 9.89 Carbamazepine-D10 
Diclofenac Na NSAID C14H10Cl2NNaO2 -ve 294.01031 10.06 4 Chlorophenol-D4 
Glyburide Anti-diabetic C23H28ClN3O5S -ve 492.13818 10.34 4 Chlorophenol-D4 
Ibuprofen NSAID C13H18O2 -ve 205.12297 10.61 4 Chlorophenol-D4 
Meclofenamic acid NSAID C14H11Cl2NO2 -ve 294.01031 10.78 4 Chlorophenol-D4 
Clotrimazole Anti-fungal C22H17ClN2 +ve 345.11676 11.28 Carbamazepine D10 
Gemfibrozil Anti-
hyperlipidemic 
C15H22O3 -ve 249.15001 11.54 4 Chlorophenol-D4 
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Table 2: Summary of method validation parameters. 
Name R2* 
Accuracy# (% 
Recovery ±SD) 
Precision (RSD %)$ 
IDL 
(ng/ml) 
IQL 
(ng/ml) 
MQL† 
(ng/L) Intra-
day** 
Inter-
day** 
Tap 
water& 
Effluent 
(1A)‡ 
Surface 
water (2G)‡ 
Metformin 0.9972 93.2 ± 6.1 4.7 6.6 6.8 9.3 10.9 0.10 0.33 9.5 
Nicotine 0.999 92.2 ± 5.8 4.1 6.4 5.6 11.6 6.9 0.50 1.67 13.3 
Acetaminophen 0.9938 96.4 ± 4.5 3.3 4.7 2.1 5.1 5.9 0.10 0.33 2.8 
Amoxicillin 0.9924 88.6 ± 3.1 2.1 3.5 3.8 12.2 7.4 1.10 3.67 22.4 
Gabapentin 0.9951 90.4 ± 5.8 7.7 6.4 9.5 <MQL 9.9 0.28 0.93 5.2 
Codeine 0.9984 92.0 ± 3.1 2.7 3.4 6.0 <MQL 9.7 0.23 0.77 5.0 
Caffeine 0.9951 101.4 ± 4.9 4.1 4.8 8.2 5.4 8.3 0.80 2.80 7.2 
Trimethoprim 0.9975 96.3 ± 4.1 3.6 4.3 1.5 11.2 7.6 0.04 0.12 2.4 
Sulfamethoxazole 0.9957 92.8 ± 3.0 2.4 3.2 4.9 13.4 3.3 0.06 0.20 3.4 
Tramadol 0.9958 91.8 ± 4.0 3.5 4.3 4.2 10.8 9.9 0.17 0.56 4.6 
Metoprolol 0.9992 93.1 ± 3.3 2.0 3.5 4.8 <MQL <MQL 0.02 0.07 2.7 
Propranolol 0.9957 95.6 ± 5.8 6.7 6.5 8.0 15.1 11.9 0.04 0.14 4.7 
Doxycycline 0.9979 85.7 ± 4.1 4.6 4.8 4.0 <MQL <MQL 0.24 0.79 22.9 
Carbamazepine 0.9749 88.2 ± 3.2 3.9 3.6 5.2 16.3 13.8 0.02 0.07 2.5 
Hydrocortisone 0.9856 83.5 ± 4.8 5.1 5.8 6.2 12.6 7.5 0.34 1.13 37.8 
Naproxen 0.9629 90.2 ± 4.7 3.4 5.2 5.4 <MQL <MQL 0.09 0.30 4.7 
DEET 0.9524 94.1 ± 4.4 4.5 4.9 3.6 <MQL <MQL 0.11 0.37 5.7 
Erythromycin 0.9920 83.5 ± 3.7 3.2 4.5 5.1 8.5 <MQL 0.25 0.84 22.0 
Oxazepam 0.9923 94.7 ± 5.3 6.3 5.6 3.4 <MQL <MQL 0.15 0.49 6.3 
Valsartan 0.9951 92.5 ± 7.3 9.1 9.9 4.5 10.3 8.2 0.32 1.05 8.6 
Mefloquine 0.9937 86.7 ± 4.5 6.3 5.2 6.0 <MQL 12.1 0.30 0.99 24.7 
17α-ethynylestradiol 0.9952 78.9 ± 5.0 5.3 6.4 6.3 <MQL <MQL 1.21 4.05 83.8 
β-estradiol 0.9951 76.9 ± 5.2 4.6 7.6 4.9 <MQL <MQL 1.16 3.87 81.0 
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Diazepam 0.9739 94.9 ± 6.8 4.7 7.2 6.3 <MQL <MQL 0.13 0.43 4.7 
Diclofenac Sodium 0.9944 89.4 ± 3.9 4.9 4.3 4.7 8.9 6.9 0.15 0.50 9.8 
Glyburide 0.9951 88.3 ± 4.5 4.2 5.1 6.2 3.5 3.6 0.30 0.99 12.9 
Ibuprofen 0.9949 90.9 ± 3.3 3.5 3.7 8.7 11.3 <MQL 0.12 0.41 8.9 
Meclofenamic acid 0.9994 86.1 ± 4.7 3.9 5.5 8.8 6.3 6.8 0.17 0.57 10.3 
Clotrimazole 0.9619 101.8 ± 4.0 3.7 3.9 6.9 13.5 8.9 0.36 1.19 16.3 
Gemfibrozil 0.9906 92.3 ± 6.6 7.4 7.2 8.7 <MQL 9.6 0.31 1.05 14.5 
* Linearity co-efficient over a range of 1-1500 ng/ml.  
# Recovery % of triplicate measurements at 3 spiked concentration levels (10, 250 and 750 ng/ml) in Milli-Q water. Details at each level are provided in the SI 
section. 
$ Relative standard deviation (RSD%) of triplicate measurements.  
** RSD% of triplicate measurements at 3 spiked concentration levels (10, 250 and 750 ng/ml) in Milli-Q water. Details at each level are provided in the SI section. 
& RSD% of triplicate analysis of tapwater samples spiked with 500 ng/L of all target PPCPs. 
‡ RSD% of triplicate analysis of un-spiked samples.  
† MQL determined in spiked tapwater. 
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Table 3: Concentrations (ng/L) of target PPCPs in the studied effluent and surface water samples. 
Name 
Effluent samples Surface water samples 
1A 1B 1C 1D 1E 2F 2G 2H 2I 2J 
Nicotine 365 736 567 835 419 116 90 269 378 98 
Metformin 219 589 5613 1109 168 32 63 23 21 36 
Acetaminophen 1509 978 15947 3042 1582 954 144 207 392 776 
Codein 63 <MQL 466 29 <MQL <MQL 18 14 21 15 
Amoxicilin <MQL 129 2038 <MQL 29 <MQL 24 <MQL <MQL 28 
Gabapentin <MQL 40 279 <MQL <MQL <MQL 8 <MQL 12 <MQL 
Trimethoprim 1060 271 2738 459 650 230 116 210 224 175 
Caffeine 84 1739 855 121 70 12 41 15 7 54 
Tramadol 353 508 1103 192 282 41 93 56 32 58 
Metoprolol 34 218 1089 67 57 17 8 5 9 12 
Sulfamethoxazole <MQL <MQL 19 <MQl <MQL <MQL <MQL <MQL <MQL <MQL 
Propranolol 8 19 187 62 <MQL <MQL 6 <MQL 7 <MQL 
Erythomycin 52 <MQL 275 106 <MQL <MQL <MQL <MQL 33 61 
Carbamazepine 63 151 342 <MQL <MQL <MQL 6 <MQL 8 1 
Hydrocortizone 43 83 128 77 46 36 43 64 42 40 
Mefloquine <MQL <MQL <MQL <MQL <MQL <MQL <MQL <MQL <MQL <MQL 
DEET <MQL <MQL <MQL <MQL <MQL <MQL <MQL <MQL <MQL <MQL 
Oxazepam <MQL <MQL 39 <MQL 10 <MQL <MQL <MQL <MQL <MQL 
Doxycycline <MQL <MQL 29 <MQL <MQL <MQL <MQL <MQL <MQL <MQL 
Clotrimazole 31 <MQL 231 <MQL 43 <MQL 23 <MQL 18 <MQL 
Naproxen <MQL 29 89 <MQL 13 <MQL 6 <MQL <MQL 8 
Diazepam <MQL 17 58 <MQL <MQL <MQL <MQL <MQL 9 <MQL 
β-estradiol <MQL <MQL 165 <MQL <MQL <MQL <MQL <MQL <MQL <MQL 
17α-ethynylestradiol <MQL <MQL 219 <MQL 104 <MQL <MQL <MQL <MQL <MQL 
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Valsartan 107 258 594 318 290 63 55 104 59 36 
Glyburide 2120 798 4162 550 1438 333 628 393 365 253 
Diclofenac Sodium 269 79 3614 172 201 35 <MQL 77 44 <MQL 
Ibuprofen 1497 1661 6702 812 1092 51 26 91 62 34 
Meclofenamic acid 17 <MQL 52 <MQL <MQL <MQL 12 <MQL <MQL <MQL 
Gemfibrozil <MQL <MQL 105 44 <MQL <MQL 17 <MQL 16 21 
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